Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$11.83 USD
+0.43 (3.77%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $11.84 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Neumora Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 454 | 372 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 24 | 16 | NA | NA | NA |
Total Current Assets | 478 | 388 | NA | NA | NA |
Net Property & Equipment | 2 | 2 | NA | NA | NA |
Investments & Advances | 10 | 24 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 1 | 4 | NA | NA | NA |
Total Assets | 496 | 426 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 0 | 7 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | NA |
Current Portion Capital Leases | 0 | 0 | NA | NA | NA |
Accrued Expenses | 21 | 12 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 0 | 2 | NA | NA | NA |
Total Current Liabilities | 25 | 24 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 0 | 0 | NA | NA | NA |
Other Non-Current Liabilities | 0 | 1 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 27 | 29 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 844 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 1,173 | 21 | NA | NA | NA |
Retained Earnings | -703 | -468 | NA | NA | NA |
Other Equity | 0 | -1 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | 469 | 397 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 496 | 426 | NA | NA | NA |
Total Common Equity | 469 | -447 | 0 | 0 | 0 |
Shares Outstanding | 152.70 | NA | NA | NA | NA |
Book Value Per Share | 3.07 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Neumora Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 372 | 423 | 454 | 510 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 27 | 20 | 24 | 16 | 0 |
Total Current Assets | 398 | 443 | 478 | 526 | 0 |
Net Property & Equipment | 1 | 2 | 2 | 2 | 0 |
Investments & Advances | 0 | 0 | 10 | 10 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 0 |
Total Assets | 404 | 450 | 496 | 545 | 0 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 0 | 2 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 18 | 19 | 21 | 23 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 23 | 25 | 25 | 29 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 26 | 27 | 32 | 0 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,197 | 1,182 | 1,173 | 1,108 | 0 |
Retained Earnings | -816 | -757 | -703 | -595 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 381 | 425 | 469 | 513 | 0 |
Total Liabilities & Shareholder's Equity | 404 | 450 | 496 | 545 | 0 |
Total Common Equity | 381 | 425 | 469 | 513 | 0 |
Shares Outstanding | 159.50 | 159.40 | 152.70 | 152.70 | NA |
Book Value Per Share | 2.39 | 2.66 | 3.07 | 3.36 | 0.00 |